Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse

Journal Title: The AAPS Journal - Year 2006, Vol 8, Issue 1

Abstract

The discovery and preclinical development of selective dopamine reuptake inhibitors as potential pharmacotherapies for treating cocaine addiction are presented. The studies are based on the hypothesis that a dopamine reuptake inhibitor is expected to partially substitute for cocaine, thus decreasing cocaine self-administration and minimizing the craving for cocaine. This type of indirect agonist therapy has been highly effective for treating smoking addiction (nicotine replacement therapy) and heroin addiction (methadone). To be an effective pharmacotherapy for cocaine addiction, the potential drug must be safe, long-acting, and have minimal abuse potential. We have developed several 3-phenyltropane analogs that are potent dopamine uptake inhibitors, and some are selective for the dopamine transporter relative to the serotonin and norepinephrine transporters. In animal studies, these compounds substitute for cocaine, reduce the intake of cocaine in rats and rhesus monkeys trained to self-administer cocaine, and have demonstrated a slow onset and long duration of action and lack of sensitization. The 3-phenyltropane analogs were also tested in a rhesus monkey self-administration model to define their abuse potential relative to cocaine. Based on these studies, 3β-(4-chlorophenyl)-2β-[3-(4'-methylphenyl)isoxazol-5-yl]tropane (RTI-336) has been selected for preclinical development.

Authors and Affiliations

F. Ivy Carroll, James L. Howard, Leonard L. Howell, Barbara S. Fox, Michael J. Kuhar

Keywords

Related Articles

Selected physical and chemical properties of commercial Hypericum perforatum extracts relevant for formulated product quality and performance

Objective. The complex composition-activity relationship of botanicals such as St John's Wort (SJW) presents a major challenge to product development, manufacture, and establishment of appropriate quality and performance...

Modeling Subpopulations with the $MIXTURE Subroutine in NONMEM: Finding the Individual Probability of Belonging to a Subpopulation for the Use in Model Analysis and Improved Decision Making

In nonlinear mixed effects modeling using NONMEM, mixture models can be used for multimodal distributions of parameters. The fraction of individuals belonging to each of the subpopulations can be estimated, and the most...

Polymeric Nanocarriers for Transport Modulation across the Pulmonary Epithelium: Dendrimers, Polymeric Nanoparticles, and their Nanoblends

The online version of this article (doi:10.1208/s12248-014-9588-5) contains supplementary material, which is available to authorized users.

Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development

While narcotic analgesics such as morphine, which act preferentially through mu opioid receptors, remain the gold standard in the treatment of severe pain, their use is limited by detrimental liabilities such as respirat...

Impact of Glycation on Antibody Clearance

Glycation of therapeutic proteins occurs during mammalian cell culture expression and upon administration to patients. Since the chemical attachment of mannose or other sugars via a chemical linker has been shown to incr...

Download PDF file
  • EP ID EP681655
  • DOI  10.1208/aapsj080124
  • Views 94
  • Downloads 0

How To Cite

F. Ivy Carroll, James L. Howard, Leonard L. Howell, Barbara S. Fox, Michael J. Kuhar (2006). Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse. The AAPS Journal, 8(1), -. https://europub.co.uk/articles/-A-681655